Clinical trials: Advanced Digestive System Tumor
Liver Cancer
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00589030
- Testing
- brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Sponsor
- City of Hope Medical Center
Pancreatic Cancer
A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic…
- Trial name
- NCT00051467
- Testing
- TNFerade
- Where
- 25 sites in United States
- Sponsor
- GenVec
Hepatocellular Carcinoma, Liver Cancer
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Advanced Adult Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04576572
- Where
- Turkey (Türkiye)
- Volunteers
- 424 people
- Sponsor
- Inonu University
Gastric Cancer
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric cancer.
- Trial name
- NCT00195572
- Testing
- Isovorin, TS-1
- Where
- 43 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pancreatic Cancer
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
This trial is a prospective, single-arm, single-center, phase II clinical study, mainly targeting subjects with locally advanced pancreatic cancer, to explore the efficacy and safety of adebrelimab combined with irinotecan…
- Trial name
- NCT06766019
- Testing
- Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
- Where
- China
- Volunteers
- 47 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer
Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.
Pancreatic, gastric, and colorectal cancers have all been shown to overexpress the gastrin gene and to be sensitive to the trophic effects of the gastrin in animal models.
- Trial name
- CC1A&B (NCT02181465)
- Testing
- G17DT
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Cancer Advances Inc.
Pancreatic Cancer
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced…
- Trial name
- NCT00016965
- Testing
- ixabepilone
- Where
- 95 sites in United States
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Rectal Carcinoma
Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer
The goal of this clinical trial is to investigate if the addition of modulated electro-hyperthermia (mEHT) improves tumor down-staging and pathological response in adult patients (20 years and above) with locally advanced rectal…
- Trial name
- mEHT (NCT07372300)
- Testing
- Hyperthermia
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Shih-Kai Hung
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Pancreatic Cancer
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
The main purpose of this study is to see primarily if BYL719 is safe to be given to patients in combination with gemcitabine and nab-paclitaxel.
- Trial name
- NCT02155088
- Testing
- BYL719, Gemcitabine, (nab)-paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with conventional treatments having little impact on disease course.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced, Pancreatic Adenocarcinoma Metastatic
- Trial name
- NEOPAX-001 (NCT01715142)
- Testing
- Gemcitabine, Abraxane
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Jean-Luc Van Laethem
Biliary Tract Cancer, Cholangiocarcinoma
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
This study is being done to see if the investigators can improve the outcome of patients with biliary tract cancer that do not qualify for surgery.
- Trial name
- NCT06546969
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Donafenib
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
This study is expected to recruit 30 patients with unresectable HCC who will be treated with Donafenib combined with PD-1 + TACE.
- Trial name
- NCT05262959
- Testing
- Donafenib, PD-1, TACE
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric Cancer, Immunotherapy
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line regimen.
- Conditions
- Gastric Cancer, Immunotherapy, Anlotinib, Toripalimab
- Trial name
- NCT04278222
- Testing
- Anlotinib Plus Toripalimab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Changzheng Hospital
Biliary Tract Cancer
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
- Trial name
- TOURMALINE (NCT05771480)
- Testing
- Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin
- Where
- 34 sites in United States, France and 6 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
Metastatic Hepatocellular Carcinoma
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
To learn about the safety and tolerability of atezolizumab, bevacizumab, and ADI-PEG 20 when given in combination to patients with locally advanced or metastatic liver cancer
- Trial name
- NCT06006286
- Testing
- Atezolizumab, Bevacizumab, ADI-PEG 20
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Carcinoma
A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma.
- Trial name
- NEOPAN (NCT02539537)
- Testing
- Gemcitabine, Folinic Acid, 5-Fluoro-uracil
- Where
- 45 sites in France
- Volunteers
- 171 people
- Sponsor
- UNICANCER
Pancreatic Cancer
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
This study is an open-label, single-arm Phase II clinical study to evaluate the efficacy and safety of ivonescimab(AK112/SMT112) in combination with stereotactic body radiation therapy and chemotherapy in patients with pancreatic…
- Trial name
- NCT06491472
- Testing
- Ivonescimab, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays and to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01107639
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 57 sites in Austria, France and 3 more
- Volunteers
- 297 people
- Sponsor
- Swiss Cancer Institute
Hepatocellular Carcinoma
Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma
Safety and efficacy of doxorubicin-eluting-bead embolization in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT02525380
- Testing
- Device(DC Bead)
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.